Filing Flows › Comparisons › KPTI vs ELTP
Karyopharm Therapeutics vs Elite Pharmaceuticals: KPTI and ELTP compared
Karyopharm Therapeutics is the larger company: $33.4M of revenue in its latest quarter (Q2 2026) against $32.4M for Elite Pharmaceuticals (Q1 FY27). Karyopharm Therapeutics is growing faster (-12% against -20% a year earlier). Elite Pharmaceuticals is more profitable, with an operating margin of 23.3% against -67.4%.
Where the money goes: KPTI and ELTP
Karyopharm Therapeutics (KPTI) · Q2 2026
Karyopharm Therapeutics, Q2 2026: revenue $33.4M (-12% year over year), operating margin -67.4%, net loss $67.0M, operating cash flow −$24.9M. The chart follows the revenue to costs, profit and cash.
Elite Pharmaceuticals (ELTP) · Q1 FY27
Elite Pharmaceuticals, Q1 FY27: revenue $32.4M (-20% year over year), operating margin 23.3%, net earnings $5.9M, operating cash flow $10.1M. The chart follows the revenue to costs, profit and cash.
| Karyopharm Therapeutics (KPTI) | Elite Pharmaceuticals (ELTP) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q1 FY27 |
| Revenue | $33.4M | $32.4M |
| Revenue growth, Y/Y | -12% | -20% |
| Gross margin | — | 41.7% |
| Operating margin | -67.4% | 23.3% |
| Net earnings | −$67.0M | $5.9M |
| Net margin | -200.5% | 18.3% |
| Operating cash flow | −$24.9M | $10.1M |
| Free cash flow | — | $9.3M |
Where the revenue comes from
Karyopharm Therapeutics
- Product: $30.8M (92%)
- License and Other: $2.7M (8%)
Elite Pharmaceuticals
- Abbreviated New Drug Applications Revenue: $32.1M (99%)
- Licensing: $221K (1%)
Questions
Which is bigger, Karyopharm Therapeutics or Elite Pharmaceuticals?
Karyopharm Therapeutics is the larger company: $33.4M of revenue in its latest quarter (Q2 2026) against $32.4M for Elite Pharmaceuticals (Q1 FY27).
Is Karyopharm Therapeutics or Elite Pharmaceuticals growing faster?
Karyopharm Therapeutics is growing faster (-12% against -20% a year earlier).
Which is more profitable, Karyopharm Therapeutics or Elite Pharmaceuticals?
Elite Pharmaceuticals is more profitable, with an operating margin of 23.3% against -67.4%.
More: Karyopharm Therapeutics earnings · how Karyopharm Therapeutics makes money · Elite Pharmaceuticals earnings · how Elite Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.